Wall Street analysts are maintaining Buy rating on Yahoo! Inc. (NASDAQ:YHOO) company shares. The one year target on the name currently stands at $37.76. The stock recently touched $31.17 and has moved in the range of $N/A during the current session. Based on a recent bid this places the stock +19.20% away from the 52-week floor of $26.15 and -32.49% away from the 52-week ceiling of $46.17.
When stocks are given “Buy” ratings by analysts, the reasons or criteria for that recommendation can greatly vary. Typically when a stock is given this label, analysts are expecting that the stock will outperform their peers, their sector or the market over a 6 to 12 month time frame. Several factors might include near-term catalysts, future earnings growth. Many analysts only give a Buy recommendation when they expect that the stock will yield a return of at least 5-10% over the course of a year. Since analyst criteria and recommendation terminology can differ, we can look at consensus numbers to get a feel of overall analyst sentiment.
Carmike Cinemas, Inc. (NASDAQ:CKEC) has been given a consensus Buy rating by analysts on Wall Street. According to Thomson Reuters' First Call, research brokers have a one year price target of $30.51 on the stock. The stock is currently trading -11.90% away from its 200-day moving average of $22.53. Based on a recent trade, shares of Carmike Cinemas, Inc. are -43.19% away from the 52-week high of $34.94 and +7.18% away from the 52-week low of $18.52.
Analysts are estimating that the company will report earnings of $-0.19 for the current year and $0.12 for next quarter. The stock closed the most recent trading session at $19.85.
Shares of Fidus Investment Corporation (NASDAQ:FDUS) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $16.10 price target and Buy rating according to the covering analysts. During today’s session the stock hit $13.01 or N/A from the previous close, while moving in the range of $N/A.
Shares of Nivalis Therapeutics Inc (NASDAQ:NVLS) continue to be viewed favorably by equities brokerage firms on Wall Street. The First Call consensus which is calculated by Thomson Reuters has a $25.00 price target according to the covering analysts. During today’s session the stock hit $4.69 or N/A from the previous close, while moving in the range of $N/A. This puts the stock -77.04% away from the 52-week high of $20.43 and +13.01% away from the 52-week low of $4.15.
Exact definitions of a “Buy” rating can greatly vary depending on the equity research firm. The consensus rating simply provides an average of those recommendations. It's important to note that a “Buy” rating does not mean that every investor should acquire the stock. It is just a single factor among many that should be considered before making an investment decision.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.